Investors Alert: Deadline Approaching in Altimmune, Inc. Class Action Lawsuit

LOS ANGELES, June 26, 2024 (GLOBE NEWSWIRE) -- Investors are duly notified about the critical deadline of July 5, 2024, to submit lead plaintiff applications in a securities class action lawsuit against Altimmune, Inc. ALT. This lawsuit pertains to those who acquired shares of Altimmune, a biopharmaceutical company dedicated to developing intranasal vaccines and therapies for liver diseases, headquartered in Gaithersburg, Maryland. Legal representation by Glancy Prongay & Murray LLP ('GPM') is available for investors who have faced potential losses due to the company's actions.

Why the Lawsuit:

The class action against Altimmune arises out of allegations that the company may have issued materially misleading business information to the investing public, causing damages to its shareholders. It is crucial for affected shareholders to participate in the class action to potentially recover their investment losses.

What This Means for Altimmune Investors:

Holding investment positions in Altimmune ALT has now become a concern for the investors, given the looming legal challenges. With the deadline nearing, being proactive is essential. Investors who purchased or otherwise acquired ALT shares and suffered losses are advised to contact GPM to assert their rights. Boasting a focus on investor welfare, GPM extends its expertise in fighting for shareholders' rights and aims to hold companies like Altimmune accountable for their alleged misdeeds.deadline, lawsuit, investors